Economic Costs and Health-Related Quality of Life Associated with Individual Specific Reminiscence: Results from the InspireD Feasibility Study

Research output: Contribution to journalArticle

Abstract

remains a dearth of research on the health costs and benefits associated with this intervention. The aim of this study was to estimate costs and quality of life associated with a home based, individual specific reminiscence intervention, facilitated by an iPad app for people living with dementia and their family carers, with a view to informing a future cost-effectiveness analysis. Use of community health and social care services, hospital services, prescribed medication and informal caregiving was assessed using an adapted version of the Client and Socio-Demographic Service Receipt Inventory (CSRI) at baseline and three-month follow-up. Quality of life was assessed at baseline, six-week and three-month follow-up using the EQ5D, DEMQOL and DEMQOL Proxy instruments. Results showed that average health and social care costs were £29,728 per person at baseline (T0) and £33,436 after 3 months (T2). Higher T2 costs were largely accounted for by higher informal caregiving costs. There was an overall increase in health-related quality of life over the duration of the intervention, although there were notable differences in index scores generated by the EQ5D (0.649, 0.652 and 0.719) and DEMQOL instruments (0.845, 0.968 and 0.901). The study concluded that a full cost–effectiveness analysis could incorporate a similar range of cost-categories with minor amendments to the CSRI to improve accuracy of cost estimation. Furthermore, a larger sample size, randomisation and longer follow-up period is required to allow potential effects of the intervention to be realised and differences between intervention and control groups to be accurately detected.
LanguageEnglish
Pages1-18
Number of pages18
JournalDementia: The International Journal of Social Research and Practice
Early online date12 Dec 2018
DOIs
Publication statusE-pub ahead of print - 12 Dec 2018

Fingerprint

reminiscence
quality of life
costs
health
economics
caregiving
dementia
amendment
medication
human being

Cite this

@article{66e9fa88b3004436add8abfe01da5204,
title = "Economic Costs and Health-Related Quality of Life Associated with Individual Specific Reminiscence: Results from the InspireD Feasibility Study",
abstract = "remains a dearth of research on the health costs and benefits associated with this intervention. The aim of this study was to estimate costs and quality of life associated with a home based, individual specific reminiscence intervention, facilitated by an iPad app for people living with dementia and their family carers, with a view to informing a future cost-effectiveness analysis. Use of community health and social care services, hospital services, prescribed medication and informal caregiving was assessed using an adapted version of the Client and Socio-Demographic Service Receipt Inventory (CSRI) at baseline and three-month follow-up. Quality of life was assessed at baseline, six-week and three-month follow-up using the EQ5D, DEMQOL and DEMQOL Proxy instruments. Results showed that average health and social care costs were £29,728 per person at baseline (T0) and £33,436 after 3 months (T2). Higher T2 costs were largely accounted for by higher informal caregiving costs. There was an overall increase in health-related quality of life over the duration of the intervention, although there were notable differences in index scores generated by the EQ5D (0.649, 0.652 and 0.719) and DEMQOL instruments (0.845, 0.968 and 0.901). The study concluded that a full cost–effectiveness analysis could incorporate a similar range of cost-categories with minor amendments to the CSRI to improve accuracy of cost estimation. Furthermore, a larger sample size, randomisation and longer follow-up period is required to allow potential effects of the intervention to be realised and differences between intervention and control groups to be accurately detected.",
author = "Ferry, {Finola R} and A Ryan and Claire-Odile McCauley and Liz/EA Laird and Aideen Gibson and Maurice Mulvenna and RR Bond and B Bunting and Kevin Curran",
year = "2018",
month = "12",
day = "12",
doi = "10.1177/1471301218816814",
language = "English",
pages = "1--18",
journal = "Dementia",
issn = "1471-3012",

}

TY - JOUR

T1 - Economic Costs and Health-Related Quality of Life Associated with Individual Specific Reminiscence: Results from the InspireD Feasibility Study

AU - Ferry, Finola R

AU - Ryan, A

AU - McCauley, Claire-Odile

AU - Laird, Liz/EA

AU - Gibson, Aideen

AU - Mulvenna, Maurice

AU - Bond, RR

AU - Bunting, B

AU - Curran, Kevin

PY - 2018/12/12

Y1 - 2018/12/12

N2 - remains a dearth of research on the health costs and benefits associated with this intervention. The aim of this study was to estimate costs and quality of life associated with a home based, individual specific reminiscence intervention, facilitated by an iPad app for people living with dementia and their family carers, with a view to informing a future cost-effectiveness analysis. Use of community health and social care services, hospital services, prescribed medication and informal caregiving was assessed using an adapted version of the Client and Socio-Demographic Service Receipt Inventory (CSRI) at baseline and three-month follow-up. Quality of life was assessed at baseline, six-week and three-month follow-up using the EQ5D, DEMQOL and DEMQOL Proxy instruments. Results showed that average health and social care costs were £29,728 per person at baseline (T0) and £33,436 after 3 months (T2). Higher T2 costs were largely accounted for by higher informal caregiving costs. There was an overall increase in health-related quality of life over the duration of the intervention, although there were notable differences in index scores generated by the EQ5D (0.649, 0.652 and 0.719) and DEMQOL instruments (0.845, 0.968 and 0.901). The study concluded that a full cost–effectiveness analysis could incorporate a similar range of cost-categories with minor amendments to the CSRI to improve accuracy of cost estimation. Furthermore, a larger sample size, randomisation and longer follow-up period is required to allow potential effects of the intervention to be realised and differences between intervention and control groups to be accurately detected.

AB - remains a dearth of research on the health costs and benefits associated with this intervention. The aim of this study was to estimate costs and quality of life associated with a home based, individual specific reminiscence intervention, facilitated by an iPad app for people living with dementia and their family carers, with a view to informing a future cost-effectiveness analysis. Use of community health and social care services, hospital services, prescribed medication and informal caregiving was assessed using an adapted version of the Client and Socio-Demographic Service Receipt Inventory (CSRI) at baseline and three-month follow-up. Quality of life was assessed at baseline, six-week and three-month follow-up using the EQ5D, DEMQOL and DEMQOL Proxy instruments. Results showed that average health and social care costs were £29,728 per person at baseline (T0) and £33,436 after 3 months (T2). Higher T2 costs were largely accounted for by higher informal caregiving costs. There was an overall increase in health-related quality of life over the duration of the intervention, although there were notable differences in index scores generated by the EQ5D (0.649, 0.652 and 0.719) and DEMQOL instruments (0.845, 0.968 and 0.901). The study concluded that a full cost–effectiveness analysis could incorporate a similar range of cost-categories with minor amendments to the CSRI to improve accuracy of cost estimation. Furthermore, a larger sample size, randomisation and longer follow-up period is required to allow potential effects of the intervention to be realised and differences between intervention and control groups to be accurately detected.

U2 - 10.1177/1471301218816814

DO - 10.1177/1471301218816814

M3 - Article

SP - 1

EP - 18

JO - Dementia

T2 - Dementia

JF - Dementia

SN - 1471-3012

ER -